Altus Life Science

Executive Summary

Altus Life Science, founded in 2018 and headquartered in San Diego, is a women’s health company focused on developing and commercializing products that address urinary incontinence and overall wellness. Its flagship product, an FDA-cleared and CE-approved urinary incontinence device, along with self-care tools and wellness products under the Phlorena™ and Asterli™ brands, positions the company in the growing women’s health market. With a mission to provide innovative, compassionate solutions, Altus aims to empower women across different life stages. Despite being private with limited financial disclosure, the company has achieved regulatory clearance for its core device, suggesting a validated product-market fit and a pathway to revenue generation. Altus operates in the diagnostics and genetics/genomics categories, though its current portfolio is centered on non-invasive devices and self-care. The company’s focus on a specific, underserved need—female urinary incontinence—offers a clear value proposition. However, its stage remains unspecified and it lacks disclosed funding or valuation, indicating an early-stage or bootstrap profile. The women’s health sector is expanding, driven by increasing awareness and demand for non-pharmaceutical interventions. Altus’s challenge will be scaling commercialization, expanding distribution, and building brand recognition against established competitors. Future growth may hinge on geographic expansion, product line extensions, or strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026European distribution expansion beyond CE-mark countries70% success
• Q1 2027Launch of a new Asterli-branded self-care product60% success
• Q4 2026Partnership or licensing deal with a major women’s health OEM50% success